FERC Orders Sample Clauses

FERC Orders. 17 FERC Part 2 Order............................18 FERC Section 203 Order.......................18 FERC Section 205 Order.......................18
Sample 1See All (4)
AutoNDA by SimpleDocs
FERC Orders. The Company, Wind LLC and each subsidiary is in compliance in all material respects with the terms and conditions of all orders issued by FERC under Sections 203, 204 and 205 of the FPA with respect to the Company, Wind LLC and each subsidiary.
Sample 1
FERC Orders. Seller shall have obtained the orders or approvals referenced in Section 7.5, above. Buyer shall have received from the Commission final orders no longer subject to rehearing on all issues regarding Buyer’s Declaratory Orderpeitition, including an order declaring that the Assets, in Buyer’s ownership and possession after Closing will not be subject to the jurisdiction of the FERC under the Natural Gas Act, and such orders shall not contain any condition or provision that is unacceptable to Buyer, in its sole discretion. ARTICLE 9ARTICLE 9
Sample 1
FERC Orders. The FERC Orders are in full force and effect, except as could not reasonably be expected to have a Material Adverse Effect.
Sample 1

Related to FERC Orders

  • Minimum Orders Client may order Manufacturing Services for batches of Products only in multiples of the Minimum Order Quantities as set out in Schedule B to a Product Agreement.

  • Stop Orders The Commission has not issued any order preventing or suspending the use of any Preliminary Prospectus or Prospectus or any part thereof.

  • FDA As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

  • Field Orders B. The documents listed in Paragraph 9.01.A are attached to this Agreement (except as expressly noted otherwise above).

  • Product Orders Product orders submitted by the Representative shall be deemed to be an offer to purchase by the purchaser, and are subject to final approval and acceptance by Ilios at its Home Office in Waltham, Massachusetts.

  • Adult Apprentices People who are 21 years of age or over at the time of entering into an apprenticeship with the Employer will be paid as per the wage rates set out in the appropriate Appendix to this Agreement. Where special or unusual circumstances occur or apply and where the parties to this Agreement and the adult apprentice agree in writing, the adult apprentice may be paid at a lesser rate, provided that the lesser rate will not be less than the rate for a junior apprentice set out in the appropriate Appendix to this Agreement.

  • Orders “Order” means the accepted order including any supporting material which the parties identify as incorporated either by attachment or reference (“Supporting Material”). Supporting Material may include (as examples) product lists, hardware or software specifications, standard or negotiated service descriptions, data sheets and their supplements, and statements of work (SOWs), published warranties and service level agreements, and may be available to Customer in hard copy or by accessing a designated HP website.

  • Pending Orders 8.1 Client has the right to place the following pending orders:

  • Court Orders ICANN will respect any order from a court of competent jurisdiction, including any orders from any jurisdiction where the consent or non-­‐objection of the government was a requirement for the delegation of the TLD. Notwithstanding any other provision of this Agreement, ICANN’s implementation of any such order will not be a breach of this Agreement

  • No Orders Neither Parent nor Merger Sub is subject to any order of any kind or nature that would prevent or materially delay the consummation of the Merger or the ability of Parent and Merger Sub to fully perform their respective covenants and obligations pursuant to this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.